(Q53518615)

15 May 2018

title

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (English)

1 reference

15 May 2018

author

Sherene Loi

9

1 reference

15 May 2018

Andrew M. Wardley

12

1 reference

15 May 2018

Paolo Nuciforo

3

object named as

P Nuciforo

1 reference

15 May 2018

19

J Baselga

1 reference

15 May 2018

W Shi

1

1 reference

15 May 2018

T Jiang

2

1 reference

15 May 2018

C Hatzis

4

1 reference

15 May 2018

E Holmes

5

1 reference

15 May 2018

N Harbeck

6

1 reference

15 May 2018

C Sotiriou

7

1 reference

15 May 2018

L Peña

8

1 reference

15 May 2018

D D Rosa

10

1 reference

15 May 2018

S Chia

11

1 reference

15 May 2018

T Ueno

13

1 reference

15 May 2018

J Rossari

14

1 reference

15 May 2018

H Eidtmann

15

1 reference

15 May 2018

A Armour

16

1 reference

15 May 2018

M Piccart-Gebhart

17

1 reference

15 May 2018

D L Rimm

18

1 reference

15 May 2018

L Pusztai

20

1 reference

15 May 2018

publication date

1 January 2017

1 reference

15 May 2018

published in

Annals of Oncology

1 reference

15 May 2018

volume

28

1 reference

15 May 2018

issue

1

1 reference

15 May 2018

page(s)

128-135

1 reference

15 May 2018

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

Targeting HER2 for the treatment of breast cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

The Cancer Genome Atlas Pan-Cancer analysis project

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5834036

13 August 2018

Identifiers

DOI

10.1093/ANNONC/MDW434

1 reference

15 May 2018

PMCID

5834036

1 reference

15 May 2018

PubMed ID

28177460

1 reference

15 May 2018